Active ingredientAlfuzosin HClCat. No. P-A074-001CAS 81403-68-1Family · Pharmaceutical analytical standards
Alfuzosin
An alpha-1 blocker patented in 1979 and approved in 1988 (in the United States in 2003): it relaxes the muscle of the prostate and urethra and eases the urinary symptoms of benign prostatic hyperplasia. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?In the early 1980s it was developed as a blood pressure drug. Curiously, it does not shrink the prostate: it acts only on smooth muscle, so urine flows more easily.
Go to the active ingredient →Active ingredientAlfuzosin HClCat. No. P-A074-001CAS 81403-68-1
Pharmacopoeial impurityAlfuzosin EP Impurity ACat. No. P-A074-002CAS 98902-36-4
Pharmacopoeial impurityAlfuzosin EP Impurity CCat. No. P-A074-003CAS 98902-34-2
Pharmacopoeial impurityAlfuzosin EP Impurity DCat. No. P-A074-004CAS 76362-29-3
Pharmacopoeial impurityAlfuzosin EP Impurity E HClCat. No. P-A074-005CAS 1796934-51-4
Pharmacopoeial impurityAlfuzosin EP Impurity FCat. No. P-A074-006CAS 19216-53-6
Isotopically labelledAlfuzosin-13C-d3Cat. No. P-A074-007
Isotopically labelledAlfuzosin-d3Cat. No. P-A074-008CAS 1006724-55-5
ImpurityAlfuzosin hydrochloride Impurity GCat. No. P-A074-009CAS 928780-95-4
ImpurityAlfuzosin Impurity 1Cat. No. P-A074-010
ImpurityAlfuzosin Impurity 2Cat. No. P-A074-011
ImpurityAlfuzosin S isomerCat. No. P-A074-012
ImpurityAlfuzosin Impurity ACat. No. P-A074-013CAS 98902-29-5No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceAlfuzosin hydrochloride CRSEDQM code A0325800Family AlfuzosinNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.